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Available online 9 February 2016AbstractPurpose: To evaluate the visual outcome and intraocular pressure changes after Visian Implantable Collamer Lens (ICL) implantation V4b and
V4c (with central hole) for correction of high myopia.
Methods: A prospective, consecutive, interventional comparative case series of V4b and V4c ICL implantation was done in high myopic patients
who were unsuitable for laser vision. The main outcome measures studied were uncorrected and corrected distant visual acuity (UDVA, CDVA),
ICL vault, intraocular pressure (IOP), endothelial cell count (ECC), and development of subcapsular lens opacities. The patients were evaluated
at postoperative 1,3,6, and 9 months.
Results: A total of 62 eyes of 32 patients (24.56 ± 4.8 years) underwent V4b ICL implantation (21 non-toric, 41 toric ICL-TICL) with
intraoperative peripheral iridectomy (PI), and 10 eyes of 5 patients (26.13 ± 3.8 years) had implantation of V4c ICL (4 non-toric, 6 TICL). The
mean preoperative manifest spherical equivalent (MSE) was 9.98 ± 2.8 D and 9.14 ± 2.4 D in the V4b and V4c groups, respectively, which
reduced to postoperative values of 0.24 ± 1.3 D and 0.2 ± 1.18 D, respectively. At the end of 9 months follow-up, mean ECC loss was 6.4%
and 6.1%, mean vault was 573.13 ± 241.13 m, and 612 ± 251.14 m, respectively, in the V4b and V4c groups. Anterior subcapsular opacities were
present in 6.9% and 3.14% of eyes with V4b and V4c groups, respectively. Four eyes from V4b (9.75%) and 1 eye from V4c (16.66%) had
rotation of more than 30 and required realignment surgery, which was done successfully. Two eyes (3.22%) with V4b ICL implantation had
high postoperative IOP (>35 mm Hg) due to blocked PI and required Nd:Yag laser iridotomy, which was done with successful control of IOP.
The safety indices were 1.11 and 1.14, and efficacy indices were 1.4 and 1.5 in the V4b and V4c groups, respectively, at the end of 9 months.
Conclusion: ICL implantation is a safe and effective surgery for correction of high myopia. Implantation of ICL with a central hole showed
negligible postoperative IOP fluctuations without a peripheral iridectomy.
Copyright © 2016, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Phakic intraocular lens (pIOL) provides internal compen-
sation of the dysfunctional refractive condition of the phakic
eye and reduces or eliminates the dependence on glasses or
contact lens.1 An implantable lens consisting of a biocom-
patible collagen copolymer (Visian Implantable Collamer lens
[ICL]; STAAR Surgical, Nidau, Switzerland) was developed* Corresponding author. Sankara Eye Center, Sivanadapuram, Sathy Road,
Coimbatore, India. Tel.: þ91 7418726929.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).in 1993 as a posterior chamber pIOL and was called the
implantable contact lens, as initially it was thought that it
would come into contact with the anterior surface of the
crystalline lens.2 Staar (Monrovia, CA, USA) patented this
material made of 60% poly-hydroxyethylmethacrylate e
HEMA, water (36%), benzophenone (3.8%), and 0.2% porcine
collagen, and called it the Collamer (collagen-copolymer).1,2
ICL is a posterior chamber phakic IOL which is a soft, flex-
ible gel-lens ushering an era of reversible refractive surgery.
ICLs are ciliary sulcus placed posterior chamber pIOLs that
can be implanted through a small (3.0 mm), self-sealing
limbal/clear corneal incision. In contrast with refractive lens
exchange, ICL implantation does not impair naturalosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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above the background rate for untreated patients with high
myopia, and have a good safety profile.3
ICL is a boon in achieving spectacle independence in pa-
tients who are unsuitable for laser refractive procedures like
those with high myopia (>13diopter D), thin corneas, those
with expected residual stromal bed thickness less than 300 m,
and severe dry eye. With its increasing acceptance and
establishment of safety profile, ICL implantation has become
an increasingly popular choice for the correction of moderate
to high myopia.4,5
The convexo-concave design of the ICL creates a vault
between it and the anterior lens surface. However, the previous
V4b ICL Model is known to cause pupillary block, and so
either a preoperative/intraoperative laser/surgical peripheral
iridotomy/iridectomy (PI) is required. To overcome this
additional step, the V4c model with a central hole (0.36 mm)
was developed in 2011. It has a central hole in addition to two
additional holes outside the optic facilitating aqueous outflow
and removal of ophthalmic viscosurgical device (OVD) during
surgery. It also helps maintain the lens nutrition.6
However, complications of ICL implantation such as cata-
ract formation (anterior subcapsular lens opacities-typical
butterfly cataract), endothelial cell loss, pigment dispersion,
intraocular pressure (IOP) elevation, and secondary glaucoma
have been reported, and these complications are expected to
increase with time.4,5 Studies have shown good acceptance
profile of both the ICL models.4,5,7
In view of the increasing prevalence of this surgical procedure,
we conducted this study to evaluate the visual outcome, compli-
cation rate and safety indices of both the V4b and V4c ICL
models for the correction of high myopia in a tertiary eye care
center in South India over a follow-up period of 9 months.
Methods
This is a prospective, consecutive, comparative, interven-
tional case series. All patients undergoing ICL implantation
for the correction of high myopia (manifest spherical equiva-
lent e MSE  6 D) were included in the study. The
following were the inclusion criteria: (a) age between 21 and
45 years, (b) stable refraction within the past 1 year, (c) pa-
tients not suitable for corneal-based laser refractive procedures
e those with abnormal corneal topography and keratoconus,
predicted thin residual stromal bed thickness of less than
300 m, high refractive errors of >13 D, severe dry eye, (d)
corneal diameter > 11 mm, (e) internal anterior chamber depth
e ACD (measured from endothelium) > 2.9 mm. Bilateral
implantation of the same ICL model for the correction of
bilateral moderate-high myopia was preferred in an individual
patient. A detail preoperative assessment was carried out
including uncorrected distant visual acuity (UDVA), corrected
distant visual acuity (CDVA), IOP measurement with non-
contact tonometry e NCT (NT-510 NIDEK technologies,
Japan) and a gonioscopy to ensure wide open angles. A
detailed slit-lamp examination to rule out any ocular pathol-
ogy was done. A detailed fundus examination to rule out anymyopia-related or other fundus pathology was done, and
prophylactic barrier laser, if required, was given. Automated
and manual keratometry values were recorded using Topcon
KR-8800 and ultrasound pachymetry using Tomey Pachy-
meter SP2000. Corneal topography was performed using
Optikon 2000 Keratron Scout topographer (Optikon, Italy) and
axial length and anterior chamber depth (ACD) by Sonomed
PacScan 300A (Sonomed, INC., USA). The White-to-White
(WTW) diameter was measured using a digital biometric
ruler-digital calipers. Endothelial cell count (ECC) was
measured using Tomey EM-3000 specular microscope (Tomey
corporation, Japan). The ICL power was calculated using the
Staar Surgical Customer Service Department formula that uses
the ACD, mean keratometry or simulated keratometry values,
central corneal pachymetry, horizontal WTW distance, and
refraction 12 mm from the corneal vertex. The horizontal axis
was marked with the patient sitting at the slit lamp prior to the
surgery. Two dots were placed on the corneal-limbal area with
a surgical marker indicating 0 and 180 meridians as reference
for later toric ICL (TICL) alignment.Surgical techniquePupillary dilatation was achieved with a combination eye-
drop containing 1% tropicamide and 2.5% phenylephrine.
0.5% proparacaine was the topical anesthetic used. With a
temporal approach, two 1 mm paracenteses were made using
angled keratome or 15 side port knife at 12 and 6 o'clock
positions. Hypromellose 2% (Viscomet PF, Unimed technol-
ogies) viscoelastic was injected into the anterior chamber
taking care not to overfill the chamber. A temporal 3 mm clear
corneal incision was made. The ICL was loaded into the
cartridge. The paracenteses were used to position the foot-
plates under the iris using the special manipulating in-
struments like Vukich's manipulator. It was ensured that all
haptics were posterior to the iris. In case of V4b ICL, the pupil
was constricted with carbachol (MIO-CHOL, 0.01% preser-
vative free, USA, marketed in India by Appasamy associates),
and a single PI at 1 the o'clock position was done with
vitrector under viscoelastic cover. In case of V4c ICL, this step
was skipped. In case of TICL proper alignment was ensured.
At the end of surgery, viscoelastic was cleared from the AC.
A standard postoperative regime consisting of topical
prednisolone acetate 1% (Pred forte, Allergan, USA) 4 times a
day for 5 days tapering over 2 weeks and topical gatifloxacin
0.3% (Zymaxid, Allergan Las, Irvine, USA) 4 times a day for
2 weeks was started. Timolol maleate eyedrops 0.5% (Timolet,
Sun Pharmaceuticals, India) was also started 2 times per day
for 3 days. Postoperatively, the patient was examined at 4 h to
check for proper ICL positioning and vaulting on slit lamp,
and IOP was checked. The patient was then followed on
postoperative day 1, 1 week, 1 month, 3 months, 6 months,
and 9 months. The main surgical outcomes were evaluated at
1, 3, 6, and 9 months follow-up. At each of these visits,
UDVA, CDVA, MSE, IOP, ICL vaulting, and ECC were
evaluated. ICL vault was measured by anterior segment optical
coherence tomography (AS-OCT) RTVue (Model-RT100
Fig. 1. Showing endothelial cell loss over the follow-up period in both the ICL
groups.
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jective symptoms of glare and haloes at the end of follow-up
period of 9 months.
The safety index was calculated by dividing the post-
operative CDVA (in decimal) at 9 months by the preoperative
CDVA (in decimal). The efficacy index was calculated by
dividing the postoperative UDVA (in decimal) by the preop-
erative UDVA (in decimal).
The data were analyzed using SPSS version 20 (Statistical
Package for Social Sciences) with paired t-test for intragroup
comparison and Mann Whitney U value test for intergroup
comparisons. A p value less than 0.05 was considered
significant.
Results
A total of 62 eyes of 32 patients with a mean ± SD age of
24.56 ± 4.8 years underwent V4b ICL implantation (21 non-
toric, 41 toric ICL-TICL) with intraoperative peripheral iri-
dectomy (PI), and 10 eyes of 5 patients with a mean ± SD age
of 26.13 ± 3.8 years had implantation of V4c ICL with central
hole ( p ¼ 0.81) (4 non-toric, 6 TICL). The large difference in
the number of eyes in the two groups is due to the later
development of the V4c model. The mean preoperative man-
ifest spherical equivalent (MSE) was 9.98 ± 2.8 D and
9.14 ± 2.4 D in the V4b and V4c groups, respectively
( p ¼ 0.51), which reduced to postoperative values of
0.24 ± 1.3 D and 0.2 ± 1.18 D, respectively ( p ¼ 0.09).
The MSE reduced significantly in the two groups ( p < 0.001
in both the groups). The mean preoperative astigmatism was
1.7 ± 1.5 diopter cylinder (Dcyl) and 1.8 ± 1.5 Dcyl which
respectively reduced to 0.7 ± 0.7 Dcyl and 0.8 ± 0.4 Dcyl
at 9 months ( p < 0.001 in both the groups) (Table 1). A gain of
1 line of CDVAwas seen in 10% and 11.76% eyes in V4b and
V4c groups, respectively ( p ¼ 0.08), while no change in
CDVA was seen in 90% and 88.24% of eyes ( p ¼ 0.07). No
eye had loss of lines of CDVA post surgery. At the end of 9
months follow-up, mean ECC loss was 6.4% and 6.1% (Figs. 1
and 2) ( p ¼ 0.08), mean vault was 573.13 ± 241.13 m, and




Age (years) 24.56 ± 4.8
Sex Males (n) 21
Females (n) 11
TICL (n) 41
Preoperative MSE (D) 9.98 ± 2.8
Postoperative MSE (D) at 9
months
0.24 ± 1.3




MSE e manifest spherical equivalent, D e diopter, cyl e cylinder.
a Paired t test.( p ¼ 0.02) (Fig. 3). Anterior subcapsular opacities were pre-
sent in 6.9% and 3.14% of eyes with V4b and V4c groups,
respectively ( p < 0.01). Four eyes from V4b (9.75%) and 1
eye from V4c (16.66%) groups had rotation of more than 30
and required re-alignment surgery which was done success-
fully (Fig. 4). Two eyes (3.22%) with V4b ICL implantation
had high postoperative IOP (>35 mm Hg) due to blocked PI
and required Nd:Yag laser iridotomy which was done with
successful control of IOP. The safety indices were 1.11 and
1.14 and efficacy indices were 1.4 and 1.5 in the V4b and V4c
groups, respectively, at the end of 9 months. At the end of 9
months, on questioning, the most common subjective symp-
tom reported was glare and haloes in 23% and 25% in the two
groups, respectively ( p ¼ 0.09). However, they were not
annoying enough to cause visual disability. Due to the large
difference in the sample size between the two groups, the
results of the intergroup comparisons done by the Mann
Whitney U value test with p values is limited and need to be
considered accordingly.
Discussion
Phakic intraocular lens implantation is so far the only
refractive treatment for high myopia that offers preservation of
accommodation and potential reversibility.p Value V4b
groupa
V4c ICL







<0.001 9.14 ± 2.4 <0.001
0.2 ± 1.18
<0.001 1.8 ± 1.5 <0.001
0.8 ± 0.4
Fig. 2. Showing intraocular pressure changes preoperatively and postoperatively
in both the ICL groups.
Fig. 4. Showing complications noted in both the ICL groups during the follow-
up period.
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without the central hole showed a satisfactory visual outcome
which was maintained at the end of 9 months follow-up
period.
Huseynova et al.8 and Ferrer-Blasco et al.9 also found
similar results with the two models with both providing good
visual outcome and no difference in the objective scatter index
and higher order aberrations.
ICLs have emerged as a successful and promising modality
for the treatment of moderate to high myopia especially in
candidates unsuitable for laser refractive procedures.10,11
Though being an intraocular procedure, it provides the
advantage of reversibility and an acceptable safety profile.
With the advent of toric ICL, a significant amount of astig-
matism can be corrected.12 The TICL have shown to be stable
over a long term period with the haptics enforcing stable lens
position in the ciliary sulcus.13 The TICL is fundamentally
different from toric intraocular lenses as it is not subject to
contraction of the capsular bag. The soft footplates of the ICL
conform to the normal undulating contours of the ciliary sul-
cus with a kind of lock-and-key situation where the footplates
will drape over and into the tiny irregular features of the
sulcus. This prevents excessive lens movement. In our study,
we had 4 from V4b (9.75%) and 1 eye from V4c (16.66%)
groups requiring realignment surgery with successful out-
comes. Lee et al. found an incidence of 1.7% of rotation inFig. 3. Showing central vault changes in both the ICL groups during the
follow-up period.excess of 10 with 98.3% showing excellent rotational stability
without decrease in visual acuity.14
There were no reports of excessive pigment dispersion or
secondary glaucoma in our study. The IOP was maintained
below 21 mm of Hg in both the groups over 9 months.
Higueras-Esteban et al.7 found no significant changes be-
tween the V4b and V4c models with respect to IOP stability.
Kawamorita et al.6 studied the fluid dynamics of aqueous
humor in V4c model and suggested that Hole-ICLs improve
the circulation of aqueous humor to the anterior surface of the
crystalline lens. Sanders15 reported approximately 6e7% of
eyes developing anterior subcapsular opacities at 7 year
following ICL implantation but only 1e2% had progressed to
clinically significant cataract in the same period, especially in
high myopes and older patients.12 Fernandes et al. also found
cataract as the major complication.16 In our study, none of the
eyes had visually significant cataract at the end of 9 months
follow-up period.
In a study conducted by Pothireddy et al.17 in India, the
safety index was 0.75, and the efficacy index was 1.04 twelve
months postoperatively. ICL was thus evaluated to be a safe
and effective procedure in terms of visual outcome. Pineda-
Fernandez et al. reported MSE in 61.1% and 22% of eyes
within ±1.00 D and ±0.50 D of emmetropia.18 In their study,
the mean residual sphere was 0.25 D, and mean residual
cylinder was 0.12 Dcyl. Insignificant refractive change
during follow-up after ICL implantation with similar results
was obtained by Igarashi et al.19
A study by Dejaco-Ruhswurm et al. demonstrated rapid cell
loss until 1 year postoperatively, after which the rate of loss
was no longer statistically significant.20,21 In our study, the
vitrector PI had clean cuts with minimum pigment dispersion
and a chance of being incomplete or getting blocked. IOP was
stable throughout the 9 months of follow-up in both the
groups. In the V4c group, this could be attributed not just to
the centraflow technology, but also to the negligible pigment
dispersion due to avoidance of PI. None of our cases devel-
oped secondary glaucoma following excessive vault or
80 V. Bhandari et al. / Journal of Current Ophthalmology 27 (2015) 76e81pigment dispersion during the follow-up. In our study, the ICL
vault was maintained at 9 months follow-up period.22,23
Kamiya et al.24 found the vault of the new central hole
pIOL to be essentially equivalent to the vault of the conven-
tional pIOL, suggesting that the presence of the central hole
did not significantly affect the vault or the refractive accuracy.
Kamiya et al.25,26 found the V4c ICL with aquaport
essentially equivalent in the optical quality variables to con-
ventional ICL implantation. They suggested that the presence
of the central artificial hole does not significantly affect the
optical quality and the intraocular scattering after surgery.
Other studies27e30 have also found good optical quality results
with V4b and V4c ICLs. Maroccos et al.31 studied pIOLs and
found that V4b ICL implantation leads to decreased night
vision performance with glare and haloes. Lyu et al.32 found a
common incidence of glare and haloes after ICL implantation.
Many studies33e38 have shown good visual performance and
quality of life after ICL implantation. In our study, patients in
both groups experienced glare and haloes, but they were
visually insignificant and non-annoying.
ICL thus offers a safe, effective, and reversible option for
correction of high myopia. However, evaluation of the inci-
dence of cataract formation and endothelial cell loss over a
decade should be carried out.
This study has several limitations. The small sample size and
unequal number of patients in the two groups precludes definite
conclusion. Also, including both eyes of one patient in the
study, limits the conclusion. ICL with a central hole offers an
added advantage of annulling a PI and providing a stable IOP.
However, a larger sample size undergoing V4c implantation
with a longer follow-up is required for confirming the results.
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